System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Marianne Pavel is an expert in Endocrinology at Charité - University Medicine Berlin (Germany). As of October 2026, ScienceLeadR ranks Marianne Pavel in the top 1% of experts worldwide for Carcinoma. Marianne Pavel has authored 333 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 2 of them ongoing. SLR score: 1,331 (community average: 125). How the SLR is computed.

LeadR Profile

Marianne Pavel Charité - University Medicine Berlin Germany
1 331 ScienceLeadR Reputation 1331

Unlock

Register Login
Network Map

Endocrinology

Subspecialties: Oncology - Pharmacy - Neurology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2003 - 2026
Source: PubMed

University of Erlangen-Nuremberg

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 333

Citations

Citations: 33 009 1st author: 42 Last author: 39 Unique author: 2

Main journals

Neuroendocrinology 63
J Clin Oncol 52
Ann Oncol 21
Endocr Relat Cancer 14
J Neuroendocrinol 9

Best Journals

Ann Oncol 10
J Clin Oncol 9
Lancet Oncol 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
[ 177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial.
PMID 42604001 — somatostatin, progression-free survival, disease progression, receptors, somatostatin, octreotide		EClinicalMedicine20260
Molecular Imaging and Radioligand Therapies in Pheochromocytomas and Paragangliomas.
PMID 42454478 — paraganglioma, somatostatin, pheochromocytoma, neoplasms, therapeutics, molecular imaging, endocrine system diseases		Endocr Relat Cancer20260
Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).
PMID 42398521 — somatostatin, neoplasms, neuroendocrine tumors, receptors, somatostatin, wounds and injuries		Lancet Oncol Top journal20261
[ 177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
PMID 42392118 — asthenia, progression-free survival, drug-related side effects and adverse reactions, everolimus, therapeutics		Lancet Top journal202610
Clinical Presentation and Outcomes of Sporadic Neuroendocrine Neoplasms in Young Adults.
PMID 42295008 — neoplasms, hormones		Eur J Endocrinol20260

Clinical Studies 19

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 12
Phase 2 4
N/A 2
Phase 2/Phase 3 1

By status:

Completed 14
Active not recruiting 2
Recruiting 2
Terminated 1

By type:

Interventional 17
Observational 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 16

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with standard chemotherapy
2025-523869-22-00 — neoplasms, multiple chronic conditions, drug therapy, therapeutics, etoposide, carboplatin, carcinoma, neuroendocrine, chemotherapy, carcinoma		Phase 3Recruiting2026
Study to evaluate the efficacy and safety of 177Lu Lu DOTA TATE in patients with Grade 1 and Grade 2 advanced GEP NET (NETTER 3)
2024-518325-15-00 — safety, neoplasms, multiple chronic conditions, neuroendocrine tumors, cost of illness		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS